Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nebokitug - Chemomab Therapeutics

Next Previous
Drug Profile

Nebokitug - Chemomab Therapeutics

Alternative Names: CM-101 - Chemomab Therapeutics

Latest Information Update: 28 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chemomab Therapeutics
  • Class Anti-inflammatories; Antifibrotics; Hepatoprotectants; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Chemokine CCL24 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary sclerosing cholangitis; Systemic scleroderma; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Hepatic fibrosis; Non-alcoholic steatohepatitis; Primary sclerosing cholangitis
  • No development reported Idiopathic pulmonary fibrosis; Non-alcoholic fatty liver disease; Systemic scleroderma

Most Recent Events

  • 14 Aug 2025 Nebokitug is available for licensing as of 14 Aug 2025
  • 11 Jun 2025 Chemomab Therapeutics completed a Type C meeting with US FDA
  • 11 Jun 2025 Chemomab Therapeutics announces intention to submit BLA to US FDA for Primary sclerosing cholangitis

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top